Hims & Hers stock plunges after Novo Nordisk ends its brief partnership
Hims & Hers stock plunged 35% on Monday after its collaboration with Novo Nordisk came to a halt.
The Danish pharmaceutical giant said it was ending the partnership because Hims is selling and promoting a cheaper copycat of Novo's blockbuster weight loss drug, Wegovy.
"Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk," Novo said in a statement on Monday.
Novo added that according to its investigation, telehealth companies that compound semaglutide drugs use ingredients "manufactured by foreign suppliers in China."
Novo said that Hims would no longer have direct access to Wegovy. Novo's stock closed more than 5% lower on Monday.
In a statement on X on Monday, Hims' CEO Andrew Dudum said Novo was being anti-competitive and that Hims will continue to provide a range of treatments, including Wegovy.
"In recent weeks, Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients," he wrote. "We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice."
Hims' stock has been on a roller coaster this year, with shares dropping and jumping sharply on new developments in the weight loss drug industry.
At the end of April, Hims stock surged 20% after Novo announced a long-term collaboration with Hims to make obesity treatments accessible on the Hims platform.
The announcement came just months after Hims' CEO said that the company would no longer sell compounded versions of Novo's weight loss drugs. Instead, it would sell "personalized" dosages of Wegovy under rules allowing it for clinical reasons such as decreased side effects. The company's stock fell over 19% following Dudum's remarks on Novo.
The company was allowed to make legal copies of Novo's weight loss and diabetes drugs Ozempic and Wegovy during a shortage that began in 2022. In February, the US Food and Drug Administration removed semaglutide injection products from its shortage list and gave compounders 60-90 days to stop making copies.
Hims is up 74% this year. Novo is down 19% this year on worries that the company is rapidly losing market share to American pharmaceutical rival Eli Lilly.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Henderson County home listings asked for less money in May - see the current median price here
The median home in Henderson County listed for $246,400 in May, slightly down from the previous month's $247,150, an analysis of data from shows. Compared to May 2024, the median home list price decreased 1.6% from $247,425. The statistics in this article only pertain to houses listed for sale in Henderson County, not houses that were sold. Information on your local housing market, along with other useful community data, is available at Henderson County's median home was 1,714 square feet, listed at $148 per square foot. The price per square foot of homes for sale is up 28.7% from May 2024. Listings in Henderson County moved steadily, at a median 52 days listed compared to the May national median of 51 days on the market. In the previous month, homes had a median of 46 days on the market. Around 36 homes were newly listed on the market in May, a 28.6% increase from 28 new listings in May 2024. The median home prices issued by may exclude many, or even most, of a market's homes. The price and volume represent only single-family homes, condominiums or townhomes. They include existing homes, but exclude most new construction as well as pending and contingent sales. Across the Evansville metro area, median home prices rose to $280,000, slightly higher than a month earlier. The median home had 1,879 square feet, at a list price of $151 per square foot. In Kentucky, median home prices were $314,900, a slight increase from April. The median Kentucky home listed for sale had 1,828 square feet, with a price of $172 per square foot. Throughout the United States, the median home price was $440,000, a slight increase from the month prior. The median American home for sale was listed at 1,840 square feet, with a price of $234 per square foot. The median home list price used in this report represents the midway point of all the houses or units listed over the given period of time. Experts say the median offers a more accurate view of what's happening in a market than the average list price, which would mean taking the sum of all listing prices then dividing by the number of homes sold. The average can be skewed by one particularly low or high price. The USA TODAY Network is publishing localized versions of this story on its news sites across the country, generated with data from Please leave any feedback or corrections for this story here. This story was written by Ozge Terzioglu. Our News Automation and AI team would like to hear from you. Take this survey and share your thoughts with us. This article originally appeared on Henderson Gleaner: Henderson County home listings asked for less money in May - see the current median price here
San Francisco Chronicle
44 minutes ago
- San Francisco Chronicle
World shares rally after Trump announces what appears to be a shaky Israeli-Iran ceasefire
BANGKOK (AP) — Stocks rallied and oil prices fell on Tuesday after U.S. President Donald Trump announced what appears to be a shaky ceasefire in the Israel-Iran war. A tentative truce proposed by Trump remained uncertain after Israel said Iran had launched missiles into its airspace less than three hours after the ceasefire went into effect. It vowed to retaliate. Still, investors took heart after Trump said Israel and Iran had agreed to a 'complete and total ceasefire' soon after Iran launched limited missile attacks Monday on a U.S. military base in Qatar, retaliating for the American bombing of its nuclear sites over the weekend. The future for the S&P 500 gained 0.8% while that for the Dow Jones Industrial Average was up 0.6%. 'The Middle East may still be smoldering, but as far as markets are concerned, the fire alarm has been shut off,' Stephen Innes of SPI Asset Management said in a commentary. In early European trading, Germany's DAX leaped 1.8% to 23,679.64, while the CAC 40 in Paris added 1.2% to 7,631.07. Britain's FTSE 100 was up 0.4% at 8,789.91. In Asia, Tokyo's Nikkei 225 rose 1.1% to 38,790.56 and the Hang Seng in Hong Kong gained 2.1% to 24,177.07. The Shanghai Composite index climbed 1.2% to 3,420.57. In South Korea, the Kospi jumped 3% to 3,103.64, while Australia's S&P/ASX 200 gained 1% to 8,555.50. Taiwan's Taiex rose 2.1% and India's Sensex was up 0.6%. In Bangkok, the SET surged 2.5%. Oil prices fell further, after tumbling on Monday as fears subsided of an Iranian blockade of the Strait of Hormuz, a vital waterway for shipping crude. The price of oil initially jumped 6% after trading began Sunday night, a signal of rising worries as investors got their first chance to react to the U.S. bombings. But it quickly shed all those gains, with U.S. benchmark crude falling 7.2%. It dropped further early Tuesday, giving up 2.4% to $66.85 per barrel. It had briefly topped $78. Brent crude, the international standard, shed 2.4% early Tuesday to $68.83. U.S. stocks rallied on Monday despite the United States' bunker-busting entry into its war with Israel. The S&P 500 climbed 1% and the Dow industrials gained 0.9%. The Nasdaq composite index advanced 0.9%. Iran's retaliation for the U.S. attacks appeared not to target the flow of oil. The fear throughout the Israel-Iran war has been that it could squeeze supplies, pumping up prices for crude, gasoline and other products. Back in the U.S., Treasury yields eased after a top Federal Reserve official said she would support cutting rates at the Fed's next meeting, as long as 'inflation pressures remain contained.' The yield on the 10-year Treasury held steady at 4.33% from 4.38% late Friday. The two-year Treasury yield, which more closely tracks expectations for the Fed, dropped to 3.83% from 3.90%. The Federal Reserve has been hesitant to cut interest rates this year because it's waiting to see how much higher tariffs imposed by Trump will hurt the U.S. economy and raise inflation. Inflation has remained relatively tame recently, but higher oil and gasoline prices would push it higher. That could keep the Fed on hold because cuts to rates can fan inflation while they also give the economy a boost. On Wall Street, Elon Musk's Tesla was the single strongest force pushing the S&P 500 higher after jumping 8.2%. The electric-vehicle company began a test run on Sunday of a small squad of self-driving cabs in Austin, Texas. It's something that Musk has long been touting and integral to Tesla's stock price being as high as it is.
Yahoo
an hour ago
- Yahoo
Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of billionaire Stan Druckenmiller's top stock picks with huge upside potential. With a price target of $63, Piper Sandler analysts reaffirmed their Overweight rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on June 6. The analysts drew attention to the upcoming Phase 3 topline readout of the CALIBRATE study for BridgeBio Pharma's calcilytic medication encaleret. The study's findings are expected to be made public in the second half of 2025. According to the analysts, the CALIBRATE study, which includes 67 individuals with autosomal dominant hypocalcemia type 1 (ADH1), is expected to have a favorable outcome given the positive efficacy findings from the Phase 2b study of encaleret in patients with ADH1. With a 40% discount, they calculated that risk-adjusted peak sales for ADH1 in the American and EU markets would amount to $389 million. This figure is equivalent to about 9% of BridgeBio Pharma's overall product revenue. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that was founded to discover, develop, evaluate, and market cutting-edge medication to cure genetic illnesses. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
